Please wait
HEALTHCARE · Pharmaceutical Preparations · Price, fundamentals, signals, and forward-looking context in one research view.
HEALTHCARE
₦223B
1.6%
18.33
Current price
₦79.00
+2.6% todayUpdated 15 min ago
Open
₦77.00
Previous close
₦77.00
Day range
₦77.00 – ₦79.00
Volume
1,283,775
18.3x P/E
Awaiting filing
1.6% yield
65/100 measured
Moderate liquidity
Recent price movement, key market context and the latest company information.
The latest saved price history for FIDSON, with its range and direction at a glance.
45 pages were reviewed. Open the update for the summary and original document.
Fidson Healthcare Plc manufactures and distributes pharmaceutical products in Nigeria. The company operates in three segments: Over-the-Counter, Ethical Products, and Consumer Healthcare Product. It offers drugs, infusions, capsules, syrups, tablets, and injectables. The company also provides products for anti-infective and anti-malaria, central nervous system, and cough and cold, gastrointestinal medicines; supplements; topical/dermatological medicines; vitamins and minerals; and ophthalmic solutions. Fidson Healthcare Plc was incorporated in 1995 and is headquartered in Lagos, Nigeria.
Investors usually follow FIDSON for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 80/100 while turnover is thin at 0.027%. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Sentiment
Market mood from flow, events, and attention.
Latest net profit
₦11.6B
TTM (2026-08-31)
ROE
32.7%
Return on equity
ROA
12.3%
Return on assets
Debt / equity
0.41
Lower is usually safer.
P/B ratio
3.77
Useful for book value support.
Dividend yield
1.6%
Current income signal.
77/100
Direction
Cautious
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Fair value
₦76.98
Analyst view
n/a
Forecast refresh
Updated 11h ago
Quality score
79
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
11.2
Momentum is weak and the stock is in oversold territory.
Recent trend
Falling
-21.0% across the latest saved price window.
Volatility
Moderate
Beta is 0.83. Price sensitivity is broadly around the market range.
52-week position
42% of range
Price is sitting around the middle of its 52-week range.
Volume confirmation
2.06x average
Trading activity is above average, giving the current move stronger participation.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
q1_2026_gdp_growth
FIDSON may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
policy_stability_and_support
FIDSON may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
local manufacturing / import substitution
FIDSON may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
FIDSON may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
FIDSON may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
FIDSON may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
FIDSON may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
FIDSON
Fidson Healthcare Plc
Price: ₦79.00
P/E: 18.33
Yield: 1.6%
EKOCORP
Eko Corporation Plc
Price: ₦5.80
P/E: N/A
Yield: N/A
MAYBAKER
May & Baker Nigeria Plc
Price: ₦37.00
P/E: 11.71
Yield: 1.1%
MECURE
MeCure Industries Plc
Price: ₦56.20
P/E: 31.17
Yield: 0.6%
Industry
Pharmaceutical Preparations
Founded
1995
Employees
732
Exchange
NGX
Ticker
FIDSON
FIDSON HEALTHCARE PLC- QUARTER 2 - FINANCIAL STATEMENT FOR 2026
2026-07-24
FIDSON HEALTHCARE PLC- QUARTER 2 - FINANCIAL STATEMENT FOR 2026
2026-07-24
₦2.29B
Book value / share
20.42
